New drug aims to stop Cancer's comeback after bone marrow transplant
NCT ID NCT06543381
Summary
This early-stage trial is testing whether a drug called olutasidenib can safely prevent certain blood cancers from returning after a patient has received a donor bone marrow transplant. The study will enroll about 15 adults with acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia who have a specific genetic change (IDH1 mutation). Participants will take the oral drug for up to two years after their transplant to see if it helps keep the cancer away.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cleveland Clinic Cancer Center
NOT_YET_RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.